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Abstract
Objectives: Ankylosing spondylitis (AS) is a chronic, progres-
sive immune-mediated inflammatory disease, driven pri-
marily by Th1 and Th17 cells. Anti-TNF therapies are success-
fully used in AS to achieve and maintain remission. However, 
their influence on the composition of T-cell subsets is not 
clear. We aimed to characterize the changes in the T-cell rep-
ertoire after a long-term anti-TNF treatment in AS patients. 
Methods: Twenty-two AS patients under long-term anti-TNF 
therapy were evaluated (15 anti-TNF responders and 7 non-
responders). A wide range of cell subtypes was analyzed 
with flow cytometry and compared with therapy-naïve and 
short-term data too. Results: Key findings include decreased 
proportions of naïve CD4 and CD8 cells, increased frequen-
cies of Th1 and Th17 cells and higher Th1/Th2 ratios in the 
long-term anti-TNF-treated patients (responders, nonre-
sponders and total), which was found to be significant not 
only when compared with healthy controls, but also with 
therapy-naïve and short-term anti-TNF-treated AS patients. 
We noted several alterations within the various activated T-
cell subsets – increase in CD4HLADR cells in responders, in 
CD8HLADR cells in the whole AS group and in responders, 
and in CD4CD25 cells in responders, and decrease in 
CD4CD69 cell percentages in long-term treated patients – 
becoming evident only after long-term anti-TNF therapy. 
Conclusions: This study provides a comprehensive assess-
ment of the impact of anti-TNF therapy on the T-cell reper-
toire in AS. Changes in T-cell phenotype seem to develop 
progressively during therapy, even in inactive disease, and 
reflect an ongoing effector T-cell differentiation and activa-
tion, along with the parallel compensatory increase in regu-
latory T cells. © 2017 S. Karger AG, Basel
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory 
rheumatic disease, characterized by the coexistence of 
chronic, progressive inflammation of the axial skeleton 
(spondylitis) and peripheral joints and of new bone for-
mation that eventually leads to ankylosis [1, 2]. The 
pathogenesis of AS has still remained only partly ex-
plored, but a strong association with the MHC class I al-
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lele HLA-B27 [3] and a perpetual activation of both the 
innate and the adaptive immune systems, in particular of 
the IL-23/IL-17 axis and of Th1 effector T-cell lineage 
with the overproduction of tumor necrosis factor-α 
(TNF-α), are considered to be key steps [4].
Chronic hyperactivation of T lymphocytes and subse-
quent skewing of functional subgroups within CD4- and 
CD8-positive circulating T cells have been supported by 
some human studies. Analyses of the peripheral blood T-
cell composition have revealed increased percentages of 
circulating Th17 helper lymphocytes [5] as well as in-
creased numbers of Th2 cells [6]. On the other hand, reg-
ulatory T (Treg) cells display decreased prevalence in the 
blood of AS patients suggesting that their lack may con-
tribute to the pathogenesis of the disease [7]. The balance 
of Th17 and Treg cells has a major impact on T-cell ac-
tivities during inflammatory rheumatic diseases, such as 
AS [8]. TNF-α induces the production of IL-17 and has 
an impact on the differentiation and activation of various 
T-cell subtypes, and therefore it has a significant role in 
shaping the adaptive immune system [9]. In view of the 
cardinal role of T cells in host defense, antitumor surveil-
lance and immune homeostasis, it is, therefore, important 
to know how the composition of the T-cell repertoire is 
skewed during TNF blocker therapies, since these agents 
are usually applied for several years. There are only few 
studies addressing the question of how TNF inhibitors 
influence the T-cell repertoire in AS [10–14]. Most of the 
existing examinations, however, have operated with only 
few T-cell subsets [10], and some of them examined only 
the role of Treg and/or Th17 cells [11, 12, 15]. The avail-
able articles do not make a distinction between periph-
eral and/or axial AS, and they use non-radiographic 
spondyloarthritis as an early stage of AS [10, 13] rather 
than as an individually existing entity. The applied medi-
cation is often missing from the cohort descriptions. Im-
portantly, only 1 study analyzed patients with relatively 
long-standing anti-TNF treatment (6 months) [11], 
whereas 2 further investigations, including our previous 
work, followed the T-cell repertoire only for a short time 
(6 weeks) [12, 14], although we have recently demonstrat-
ed in our study of rheumatoid arthritis (RA) patients that 
there are profound differences in the T-cell subset distri-
bution after short-term or long-term follow-up [16].
Since TNF blockers must be used for several years in 
most of the patients with AS because the symptoms would 
recur in the vast majority of patients if the drug is stopped, 
it is important to know the type and degree of the altera-
tions in the immune system developing during the long 
term, even several years of continuous anti-TNF therapy.
The aim of our comprehensive study is to give a well-
described pathogenic overview of various T-cell subsets 
in AS before and during short- and long-term anti-TNF 
therapy, as we did in our previous work in this field in RA 
[16]. We intended to examine whether there is a differ-
ence between anti-TNF responder and anti-TNF nonre-
sponder AS patients as well, and we compare the long-
term anti-TNF-treated AS patients (more than 6 months) 
with our previous data on therapy-naïve and short-term 
(6 weeks) anti-TNF-treated AS patients too.
Patients and Methods
Study Population
Long-Term Anti-TNF-Treated AS Patients
Twenty-two long-term anti-TNF-treated AS patients were en-
rolled in this study. All of them are treated at the Department of 
Rheumatology and Immunology, University of Szeged. AS was 
classified according to the modified New York criteria [17]. All the 
patients had been treated with anti-TNF agents for at least 6 
months (long-term). All AS patients were treated with the first 
TNF inhibitor in their patient history at the time of the clinical and 
laboratory assessment. We distinguished long-term anti-TNF re-
sponder (n = 15) and long-term anti-TNF nonresponder (n = 7) 
AS patients. For the definition of the therapeutic response, we used 
the ASAS 5/6 improvement criteria [18], and for remission we fol-
lowed the ASAS remission criteria set [19]. All the patients had to 
meet the ASAS criteria for responder or nonresponder status for 
at least 1 month prior to the inclusion. In the responder group, 6 
patients received infliximab, 7 adalimumab, and 2 etanercept. In 
the nonresponder group, there were 3 infliximab-, 4 adalimumab-, 
1 etanercept-, and 1 golimumab-treated AS patients.
Therapy-Naïve and Short-Term Anti-TNF-Treated AS 
Patients
To compare the effects of long-term anti-TNF therapy with ther- 
apy-naïve cases and with short-term (2 and 6 weeks) anti-TNF 
treatment, we used the cohort described in detail in our previous 
work [14].
We recorded the HLA-B27 status, the presence of peripheral 
arthritis (in addition to the axial involvement), enthesitis, uveitis, 
inflammatory bowel disease ever occurring during the course of the 
disease, the grade of sacroiliitis and the presence of AS-specific 
changes on the spine (syndesmophyte or bamboo spine) on X-ray, 
and smoking history in every AS patient. Parameters of disease ac-
tivity including C-reactive protein, erythrocyte sedimentation rate, 
and Bath ankylosing spondylitis disease activity and functional in-
dices (BASDAI and BASFI, respectively) were also registered.
Healthy Controls
The control group included 10 age- and gender-matched healthy 
volunteers (mean 42, range 29–59 years). All of them had a negative 
history of AS symptoms and a negative status upon detailed physical 
and laboratory examination. Informed consent was signed by all par-
ticipants. The study protocol had been approved by the Ethics Com-
mittee of the Ministry of Health of Hungary and the Ethics Commit-
tee of the University of Szeged (ETT-TUKEB905/PI/09).
D
ow
nl
oa
de
d 
by
: 
R
ep
rin
ts
 D
es
k
72
.3
7.
25
0.
18
8 
- 3
/5
/2
01
8 
3:
50
:2
1 
PM
Anti-TNF and T-Cell Subsets in 
Ankylosing Spondylitis
3Pathobiology
DOI: 10.1159/000484250
Flow Cytometry Measurements
The measurement protocol was identical in all aspects to what 
we had used in our previous studies [14, 20]. Blood samples were 
taken at least 6 months after the initiation of anti-TNF therapy 
(long-term follow-up). The results were also compared with those 
of the samples taken just before starting anti-TNF therapy, when 
each of the patients was under NSAID therapy alone, then in weeks 
2 and 6 after the initiation of anti-TNF therapy (short-term follow-
up) [14]. Laboratory procedures were as follows: blood samples 
were taken in the laboratory unit of the Department of Rheumatol-
ogy and Immunology. We used 15 ml of anticoagulated blood and 
separated the peripheral blood mononuclear cells by centrifuga-
tion with Ficoll-Paque (GE Healthcare Life Sciences, Pittsburgh, 
PA, USA). Peripheral blood mononuclear cells were frozen and 
kept at –80  ° C until analysis. After thawing, samples were washed 
twice with phosphate-buffered saline solution (pH 7.4). Fluores-
cent antibodies were used (Becton Dickinson, San Diego, CA, 
USA) for cell surface staining according to the manufacturer’s 
manual.
Identified cell subtypes were: CD4+ or CD8+ cells as the two 
major classes of effector T cells, Th1 cells (CD4+CXCR3+), Th2 
cells (CD4+CCR4+), Th17 cells (CD4+CCR4+CCR6+), Treg cells 
(CD4+CD25+CD127–), naïve T cells (CD45RA+), or memory T 
cells (CD45RO+). The prevalence of cells expressing early (CD69), 
intermediate (CD25), or late (HLA-DR) activation markers was 
also determined within both the CD4+ and CD8+ subsets. An av-
erage of 200,000 cells was registered for each acquisition. All mea-
surements were performed on a BD FACSAria flow cytometer 
(Becton Dickinson, San Jose, CA, USA). Cell prevalence values 
were determined with conventional gating, through the use of 
FACSDiva software (Becton Dickinson, San Jose, CA, USA).
Statistical Methods
Data are presented as means ± SD or median (25th–75th per-
centiles) depending on their distribution. Clinical parameters be-
tween responder and nonresponder patients were compared with 
the Student t test (categorical variables) or χ2 test (prevalence with-
in groups). Cell subset prevalence values were compared among 
groups with analysis of variance or with the Kruskal-Wallis test, 
with the Bonferroni or Dunn tests for multiple comparisons, re-
spectively. A p value <0.05 was taken as statistically significant.
Results
AS Patient Characteristics under Long-Term  
Anti-TNF Therapy
Anti-TNF responder and anti-TNF nonresponder AS 
patients did not differ in terms of age, disease duration, 
smoking status, prevalence of HLA-B27 positivity, pres-
ence of peripheral arthritis, or the occurrence of enthesi-
tis, uveitis or inflammatory bowel disease. Patients in 
both groups had a similar radiographic severity of sac-
roiliitis or frequency of AS-specific radiological spinal ab-
normalities. Not surprisingly, anti-TNF nonresponders 
had significantly higher mean C-reactive protein, eryth-
rocyte sedimentation rate, BASDAI and BASFI values 
(Table 1).
Table 1. Clinical characteristics of long-term anti-TNF-treated AS patients
Anti-TNF-treated
responders (n = 15)
Anti-TNF-treated 
nonresponders (n = 7)
Age, years 46 (31–63) 41 (30–57)
Disease duration, months 15 (9–40) 18 (940)
Anti-TNF therapy duration, months 6 (6–12) 6 (6–8)
Smoking ever 7 (47) 3 (43)
HLA-B27 positivity 11 (73) 5 (71)
Presence of peripheral arthritis 10 (67) 3 (43)
Presence of enthesitis 2 (13) 3 (43)
Presence of uveitis 5 (33) 1 (14)
Presence of IBD 2 (13) 1 (14)
Radiographic SI index 2.67 (2–4) 2.57 (2–4)
Presence of radiographic abnormalities on the spine 10 (67) 5 (71)
CRP*, mg/L 7 (2–36) 37 (2–100)
ESR*, mm/h 12 (1–39) 42 (5–67)
BASDAI* 1.45 (0.3–2.5) 5.8 (4.1–6.8)
BASFI* 2.0 (0.5–2.8) 5.67 (4.0–7.7)
Numbers indicate mean (range) or absolute numbers (%). AS, ankylosing spondylitis; IBD, inflammatory 
bowel disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BASDAI, Bath ankylosing spondylitis 
disease activity index; BASFI, Bath ankylosing spondylitis functional index. * p < 0.05.
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The Composition of the T-Cell Repertoire of AS 
Patients under Long-Term Anti-TNF Therapy
Our detailed analysis of the T-cell phenotypes of AS 
patients under long-term anti-TNF therapies is presented 
in Figures 1 and 2, and numerically in Table 2. Major 
findings are that all anti-TNF-treated AS patients (both 
anti-TNF nonresponders and anti-TNF responders) 
show a significantly lower prevalence of naïve CD4+ and 
CD8+ cells (CD4CD45RA+ and CD8CD45RA+), and 
higher frequencies of Th1 and Th17 cells, and Th17/Treg 
ratios than healthy controls. The proportion of Treg cells 
was similar to that in the controls. The prevalence of 
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Fig. 1. Proportions of various T-cell subsets in ankylosing spondy-
litis patient groups of long-term anti-TNF responders (resp., n = 
15), long-term anti-TNF nonresponders (nonresp., n = 7), and in 
healthy controls (n = 10). Data are presented as median (horizon-
tal line within boxes), 25th and 75th percentiles (horizontal bor-
ders of the boxes), and minimum and maximum (whiskers). a p < 
0.05 versus anti-TNF nonresponder; b p < 0.05 versus anti-TNF 
responder.
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Fig. 2. Proportions of the major effector T-helper cell subsets in 
ankylosing spondylitis patient groups of long-term anti-TNF re-
sponders (resp., n = 15), long-term anti-TNF nonresponders (non-
resp., n = 7), and in healthy controls (n = 10). Data are presented 
as median (horizontal line within boxes), 25th and 75th percentiles 
(horizontal borders of the boxes), and minimum and maximum 
(whiskers). a p < 0.05 versus anti-TNF nonresponder; b p < 0.05 
versus anti-TNF responder.
Anti-TNF 
nonresponders
(n = 7)
Anti-TNF
responders
(n = 15)
Controls
(n = 10)
CD4 39.39±16.02 30.02±17.23 40.56±7.835
CD8 16.59±13.73 16.631±2.64 22.56±8.073
CD4CD45RA 21.40±16.50 6.484±5.213a 56.761±0.34a, b
CD4CD45RO 52.041±8.71 49.87±27.97 36.49±10.05
CD4CD69 1.800±0.6677 2.159±2.514 2.109±0.7517
CD4CD25 3.791±2.766 2.420±3.745 7.444±0.8571b
CD4HLADR 5.847±2.449 14.33±14.34 2.715±0.7444b
CD8CD45RA 36.81±25.61 15.16±18.93a 70.48±8.991a, b
CD8CD45RO 21.66±5.943 18.93±9.592 22.31±7.879
CD8CD69 10.55±11.12 1.641±2.855a 1.578±0.5547
CD8HLADR 7.066±3.303 10.41±7.445 2.269±0.9214b
Th1 18.07±6.070 21.39±6.452 9.412±0.8024a, b
Th2 9.766±4.653 8.206±1.326 5.937±1.155a
Th1/Th2 2.435±1.526 2.686±0.918 1.656±0.437b
Th17 3.736±1.980 3.144±1.066 1.001±0.1746a, b
Treg 5.996±2.131 5.575±2.071 5.715±0.7965
Th17/Treg 0.765±0.599 0.697±0.685 0.178±0.036a, b
Numbers indicate mean ± SD values within the whole T-cell population (CD4 and 
CD8) or within CD4 cells (Th1, Th2, Th17, Treg and ratios), or for the other markers with-
in the CD4 or CD8 cells, as indicated. a p < 0.05 versus anti-TNF nonresponder; b p < 0.05 
versus anti-TNF responder.
Table 2. Prevalence and ratios of T-cell 
subsets in long-term anti-TNF-treated AS 
patient groups and controls
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T cells with the late activation marker (CD4HLADR and 
CD8HLADR) was higher, and of T cells with the interme-
diate activation marker (CD4CD25) it was lower, and the 
Th1/Th2 ratio was higher only in the anti-TNF respond-
ers compared to the controls. Some differences were also 
revealed between the 2 AS patient groups: in anti-TNF 
responders, the frequencies of naïve CD4+ and CD8+ 
cells (CD4CD45RA+ and CD8CD45RA+) and of early 
activated CD8CD69 cells were lower than in anti-TNF 
nonresponders.
Comparison of the T-Cell Phenotype of AS Patients 
under Long-Term and Short-Term Anti-TNF Therapy
Since we had a database on the early changes in the T-
cell repertoire in a cohort of anti-TNF-treated AS patients 
[14], we had the opportunity to compare these data with 
our present results. T-cell subset prevalence in AS pa-
tients at the time of the initiation of anti-TNF therapy, 2 
and 6 weeks thereafter (short-term) and after a long-term 
follow-up (at least 6 months after initiation of anti-TNF 
therapy) can be seen in Figures 3 and 4. In summary, the 
decrease in the proportion of naïve CD4+ and CD8+ cells 
(CD4CD45RA and CD8CD45RA), and the increase in 
that of Th1, Th17 and Treg cells, and in Th1/Th2 ratios in 
the long-term anti-TNF-treated AS patients (responders, 
nonresponders, and total) has proven to be significant 
not only when compared with the controls (see above), 
but also with therapy-naïve and short-term anti-TNF-
treated AS patients. Alterations within the various acti-
vated T-cell subsets – including increase in CD4HLADR-
positive cells in responders, and in CD8HLADR- and 
CD4CD25-positive cells in the whole long-term treated 
AS group and in responders – have also become evident 
only after long-term anti-TNF therapy.
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Fig. 3. Changes in the proportions of T-cell subsets in anyklosing 
spondylitis patient groups: comparison between short-term and 
long-term treatment. Data are presented from the initiation of an-
ti-TNF therapy; baseline: before the start of anti-TNF therapy (n = 
13); 2 weeks: after 2 weeks of anti-TNF therapy (n = 13); 6 weeks: 
after 6 weeks of anti-TNF therapy (n = 12) [14]; long-term anti-
TNF responders (n = 15); long-term anti-TNF nonresponders 
(n = 7); long-term all: the 2 long-term subgroups together (n = 22); 
healthy controls (n = 10). a p < 0.05 versus baseline; b p < 0.05 ver-
sus after 2 weeks; c p < 0.05 versus after 6 weeks; d p < 0.05 versus 
control. For CD4CD25 and CD4CD69, ANOVA revealed a sig-
nificant (p = 0.018) difference among the groups, but the Bonfer-
roni post hoc test did not identify any significant difference be-
tween the particular subgroups individually.
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Discussion
Anti-TNF therapy has revolutionized the treatment of 
immune-mediated rheumatic diseases including AS. The 
effect of cytokine neutralization as a driving force for the 
inhibition of inflammation is well exemplified by the use 
of TNF-α antibodies for the treatment of AS too. How-
ever, the knowledge of further influences of TNF inhibi-
tors either on the cellular components of the immune sys-
tem or their impact on intracellular T- or B-cell signaling 
is limited.
According to our best knowledge, the present results 
are the first in the literature that describe the composition 
of the T-cell repertoire in AS patients treated with anti-
TNF agents for a sufficiently long period and with a wide 
range of cell subtype markers allowing a comprehensive 
overview of the adaptive immune system.
Conclusions of our results are:
1. several subtypes that reflect an activation state of the 
immune system, including Th17, Th1 cells and Th1/Th2 
ratios, increased significantly during anti-TNF therapy, 
and the proportions of cells with various activation mark-
ers are also increased in AS as compared with healthy in-
dividuals,
2. the parallel compensatory increase in Treg cells was 
noted during long-term anti-TNF therapy in AS,
3. there are strikingly low proportions of naïve T cells 
(CD4CD45RA and CD8CD45RA) following long-term 
anti-TNF therapy in AS,
4. the impact of short-term and long-term anti-TNF 
therapy is different on T-cell phenotypes in AS, as most 
of the changes develop after more than 6 weeks of thera-
py, and
5. these differences exist also between short-term and 
long-term responders, which suggests that factors other 
than T-cell composition are responsible for the decrease 
in the clinical activity signs of AS.
There are many similarities in these results and our 
previous observations in RA patients [16]. The present 
measurements confirm our previous conclusions that 
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Fig. 4. Changes in the proportions of the major effector T-helper 
cell subsets in ankylosing spondylitis patient groups: comparison 
between short-term and long-term treatment. Data are presented 
from the initiation of anti-TNF therapy; baseline: before the start 
of anti-TNF therapy (n = 13); 2 weeks: after 2 weeks of anti-TNF 
therapy (n = 13); 6 weeks: after 6 weeks of anti-TNF therapy (n = 
12) [14]; long-term anti-TNF responders (n = 15); long-term anti-
TNF nonresponders (n = 7); long-term all: the 2 long-term sub-
groups together (n = 22); healthy controls (n = 10). a p < 0.05 versus 
baseline; b p < 0.05 versus after 2 weeks; c p < 0.05 versus after 6 
weeks; d p < 0.05 versus control.
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the major mechanism of action of anti-TNF therapy is 
not the restoration of the activated immune system – ob-
served in active disease – to a state similar to healthy in-
dividuals, in terms of the T-cell subset distribution. Rath-
er, some key pathogenic processes, such as Th17 and, to 
a lesser extent, Th1 predominance in AS, seem to prevail 
although the inflammatory process has been put to qui-
escence clinically and also as reflected by routine labora-
tory inflammatory markers. Another consequent finding 
is the marked reduction of naïve T cells, both in the 
CD4+ and the CD8+ compartments. This finding has 2 
potential explanations: (1) emigration of T-cell precur-
sors from the thymus or release of naïve T cells from the 
secondary lymphoid organs is impaired, or (2) differen-
tiation of memory T cells from naïve cells is accelerated. 
We propose the second explanation to be correct because 
the absolute number of T cells or the proportion of any 
other T-cell subsets is not decreased, and the permanent 
increase in the Th17 and Th1 subtypes, mainly the 2 ac-
tivated subtypes that are the key drivers of inflammation 
in AS, suggest that the generation of newly differentiated 
effector T cells remains an ongoing process despite TNF 
blockers.
It may be of relevance that some of these changes (in 
particular, the decrease in CD4 and CD8 naïve T-cell fre-
quencies and the elevation of Th1 proportions) were sig-
nificantly more pronounced in anti-TNF responders 
than in nonresponders. In this regard, Chen et al. [21] 
have found that the percentage of Th17 cells and the se-
rum concentration of IL-17 were higher in RA patients 
who subsequently became anti-TNF nonresponders, and 
in these patients these values even increased during the 
first 4 weeks of infliximab therapy. Furthermore, low 
Th17 cell frequencies predicted a good European League 
against Rheumatism response to anticytokine (including 
anti-TNF) therapies, whereas high CD24hiCD27+ Breg 
prevalences were predictors to response to abatacept in 
RA [22]. We have revealed that low CD4CD69 cell fre-
quency at the initiation of anti-TNF therapy was a good 
predictor of treatment response to anti-TNF treatment in 
RA [16]. However, data are much scarcer in relation to 
AS, in which an increase in Th17 cell frequencies has also 
been revealed during anti-TNF treatment [12], but op-
posing results have also been obtained by others [11]. 
Prospective examination of T-cell subset distribution in a 
larger number of AS patients could help answer the ques-
tion of whether these proinflammatory T-cell subsets or 
other T-cell subtypes may be associated with therapy re-
sistance or may contribute to disease relapse after the 
withdrawal of anti-TNF treatment.
The expansion of Th17 and Th1 cells has been de-
scribed by other authors too [23, 24], and we observed a 
similar phenomenon in RA too [16]. A potential expla-
nation has been presented by Notley et al. [25], who have 
shown that anti-TNF treatment of mice in the collagen-
induced arthritis model led to the upregulation of the 
p40 subunit of the IL-12/23 receptor and a resulting in-
crease in both Th17 and Th1 cell frequencies. They ex-
plained the reduction in collagen-induced arthritis ac-
tivity in anti-TNF-treated mice with their observation 
that the amount of Th1 and Th17 cells in the synovium 
markedly decreased despite the expansion of these cells 
in the blood and lymph nodes of the animals. In RA pa-
tients, Th1 and Th17 cells and IL-17 production were 
found to increase during anti-TNF therapy, and it was 
independent of the clinical response [23]. However, 
CCR6 expression was significantly downregulated in 
Th17 cells of RA patients in remission under anti-TNF 
therapy as compared with those with active disease [23]. 
These findings further support that, in spite of the in-
creased amount of the circulating proinflammatory T 
cells during anti-TNF therapy, the inactivity of the dis-
ease is maintained by alterations in various effector 
functions of these cells.
Rather, the clinically reflected inactivity of the inflam-
matory process is ensured by the sufficient number and 
effect of Treg cells, and the blockade of the key effector 
cytokines, in this case, of TNF-α. Furthermore, some in-
tracellular signaling processes that are integral parts of 
lymphocyte activation are also altered in AS. These in-
clude intracellular nitric oxide and calcium handling, as 
we have described in our previous work. There are marked 
differences in the impact of short- and long-term anti-
TNF therapy on these processes [14]. We think that it will 
be interesting to follow the T-cell repertoire in AS during 
Th17 blocker therapies (IL-23- or IL-17 inhibitors) and 
follow the long-term effects TNF blockers on intracellular 
signaling processes too.
The fact that the proportion of effector T-cell subtypes 
(Th1, Th17, and various activated T-cell subpopulations) 
does not decrease during anti-TNF therapy (in fact, they 
rather increase) may indicate that the T-cell repertoire 
necessary for an effective antitumor or antimicrobial de-
fense is not compromised even after a substantial dura-
tion of anti-TNF therapy. This may provide a potential 
explanation to the findings from registry studies of large 
patient populations that the incidence of the vast major-
ity of tumor types does not seem to increase even after 
several years of biological treatments, and, albeit with 
cautious infection surveillance and prevention, the inci-
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dence of infections is not unacceptably increased with 
prolonged anti-TNF therapy.
This study has several strengths and a few weak points 
at the same time. Advantages are the high number of T-
cell subtypes measured simultaneously and the long-term 
follow-up, since the experience from our and others’ 
studies indicates that several months are necessary until 
a new steady state in the T-cell repertoire develops during 
clinically effective biological therapies in AS. A limitation 
of this study is the comparison of partly different cohorts 
of short-term- and long-term treated AS patients. Since 
these 2 cohorts contain AS patients from the same geo-
graphical area, racial and gender composition, treated in 
the same center with identical diagnostic and therapeutic 
principles and agents, and the laboratory techniques were 
totally identical in all aspects for the measurements of 
both cohorts, we believe that the comparisons of AS pa-
tients with short- or long-term anti-TNF therapy suffi-
ciently corroborate our conclusions.
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